CRISPR Therapeutics raises $600M in convertible notes after posting Q1 net loss

Gene-editing biotech is expensive in a very specific way. You can finally get one product to market, start generating real sales, and still burn a lot of cash because the rest of the pipeline is years away. That is basically where CRISPR Therapeutics is right now. On May 4, the company reported a first-quarter 2026 net loss of $122.9 million, then pointed investors to the bigger picture — it had already raised $600 million in convertible notes in March and finished the quarter with $2.44 billion in cash, cash equivalents, and marketable securities. ### Why raise debt after getting a product approved? Because approval is not the same thing as self-funding. CRISPR Therapeutics now has CASGEVY on the market with partner Vertex for sickle cell disease and transfusion-dependent beta thalassemia, but first-quarter revenue recognized by CRISPR was $43 million — not nearly enough to cover the company’s full research and operating bill yet. So the notes deal looks less like distress financing and more like runway financing. ### What exactly did the company raise? The final deal was $600 million of convertible senior notes due 2031, completed on March 16 after the initial purchasers exercised their option for an extra $50 million. Net proceeds came to about $585.2 million. The notes carry a 1.125% coupon, with an exercise price. ### Why use convertible notes instead of selling stock? Because converts are the biotech compromise. The company gets cash now at a relatively low cash interest cost, but investors get the option to convert into equity later if the stock rises enough. That means less immediate dilution than a straight stock sale, but the catch is future dilution can still show up if the business works and the share price climbs past the conversion level. ### Was the quarter itself actually weak? Financially, yes. Revenue was low and the net loss was large. But operationally, the quarter was more mixed than bad. CASGEVY kept moving commercially, with more than 500 patients initiated globally, and management highlighted progress across its in-vivo liver programs and CAR-T pipeline. In biotech, investors often care less about a single set of clinical milestones. ### What pipeline progress mattered most? The liver-directed in-vivo programs are the part to watch. CRISPR said CTX310 is moving into Phase 1b after U.S. IND clearance to expand the trial, and it still expects clinical trial starts around mid-2026 for CTX460 and CTX340. That matters because these programs test whether the company can move beyond ex vivo editing and into treatments delivered directly inside the body — a much bigger commercial opportunity if it works. ### So what are investors really being asked to believe? That one approved product plus a giant cash pile can finance a platform transition. CRISPR Therapeutics is trying to support CASGEVY commercialization while also pushing in vivo editing, siRNA, and CAR-T programs forward at the same time. The notes deal gives management breathing room to do that without rushing back to the equity market this year. ### What’s the real risk? Time. Biotech balance sheets can look huge right before they start shrinking fast. If CASGEVY adoption ramps slower than hoped, or if the in-vivo programs slip, the company could spend years carrying debt and funding trials before another clear value inflection arrives. The cash buys patience — not proof. ### Bottom line This was not a “great quarter” story. It was a capital-structure story. CRISPR Therapeutics lost money, but it also made sure it has enough cash to keep building through 2031-style timelines — which is what this business now demands.